eligibility_summary
Eligible: adults 18–75 with ocular adnexal MALT lymphoma (WHO), TNM T1–T3 without intraconal involvement, consented. Exclude: T2/T3 with intraconal or T4, prior OAML therapy, significant cataract or need for other ocular surgery, major ocular comorbidities, HBV/HIV, long-term steroids, other drug trials, pregnancy/lactation, serious systemic disease, inability to understand. One eye only (prefer right), other eye may be treated but not analyzed, in ISRT treat larger/symptomatic eye first.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Randomized trial in primary ocular adnexal MALT lymphoma comparing: 1) Intralesional rituximab—type: chimeric anti-CD20 monoclonal antibody (immunotherapy). Mechanism: binds CD20 on B cells and depletes malignant marginal zone B cells via antibody-dependent cellular cytotoxicity, complement-mediated lysis, and apoptosis, localized injection aims to limit systemic exposure and suppress B-cell receptor–driven survival. 2) Involved-site radiation therapy (external-beam radiation). Mechanism: ionizing radiation causes DNA double-strand breaks, leading to mitotic catastrophe/apoptosis in cells within the field. Targets: CD20+ ocular adnexal B cells (lymphoma cells), radiation also affects tumor microenvironment. Key pathways: CD20-mediated B-cell cytotoxicity/clearance and DNA damage response pathways.